The peak expression of the four genes—MBOAT2, CDA, LPCAT2 and B4GALT5—is where we may use this data to improve the impact of anticancer medications on PACA patients. The gene discussed is CDA; the disease is permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.